BUZZ-Evolus rises after preliminary Q4 revenue beats estimates

Shares of cosmetic drugmaker Evolus EOLS.O rise ~33% to $14

Co says it expects Q4 rev. Of $79 mln, above analyst estimates of $77.1 mln - data compiled by LSEG

Co forecasts 2025 rev. to be between $345 mln and $355 mln vs. analyst est. of $350.1 mln

Co says it expects to receive FDA approval for its injectable hyaluronic acid, Evolysse, within the next 90 days and plans to launch in the U.S. in Q2 2025

All 7 brokerages covering the stock rate it "buy" or higher; their median PT is $25 - LSEG

EOLS gained 10.5% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))